Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis
Medical Sciences · 19.05.2026 · 14 (2) · 260
DOI: 10.3390/medsci14020260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 19.05.2026. Verfasst von Lutfi Cagatay Onar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Venous Thromboembolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Venous thromboembolism (VTE) is a thromboinflammatory disorder involving coordinated activation of coagulation, endothelial dysfunction, and inflammatory signaling. Low-molecular-weight heparins (LMWHs) may exert pharmacological effects beyond anticoagulation. This study compared enoxaparin, bemiparin, and tinzaparin and explored potential multi-target mechanisms using molecular docking, network pharmacology, and enrichment analyses.
Methods
In this retrospective cohort study, patients with acute VTE treated with therapeutic-dose LMWHs were analyzed. Stabilized IPTW based on multinomial propensity scores was used to reduce baseline imbalance between treatment groups. Clinical recovery was assessed using the Clinical Severity Score (CSS). Thromboinflammatory biomarkers (MPV, hs-CRP, NLR, fibrinogen) were evaluated during follow-up. Molecular docking, STRING/Cytoscape-based protein–protein interaction, and enrichment analyses were performed.
Results
Median time to symptom resolution was 31 days with enoxaparin, 28 days with bemiparin, and 24 days with tinzaparin (log-rank p < 0.001). Recovery was faster with bemiparin (HR 1.28, 95% CI 1.05–1.56) and tinzaparin (HR 1.72, 95% CI 1.41–2.10). Tinzaparin showed greater reductions in hs-CRP, MPV, NLR, and fibrinogen (all p < 0.05) and less analgesic use beyond 10 days (19.7% vs. 27.0% and 33.2%; p < 0.001). Docking analyses identified plausible conformations (root-mean-square deviation, RMSD ≤ 2 Å). Given the structural flexibility and heterogeneous chain length of LMWHs, rigid docking algorithms may not fully capture biologically relevant conformations. Therefore, docking results should be interpreted as qualitative interaction mapping rather than quantitative binding affinity estimation. Network analysis highlighted F3, TNF, IL6, and VWF, while enrichment analyses suggested involvement of cytokine signaling, leukocyte migration, and thromboinflammatory pathways.
Conclusions
LMWH therapy was associated with improved thromboinflammatory markers and clinical recovery, with tinzaparin showing comparatively more favorable thromboinflammatory biomarker trajectories and recovery dynamics within the limitations of this observational analysis. Integrated clinical and in silico findings provide hypothesis-generating insights into potential multi-target pharmacological effects beyond anticoagulation; however, these observations should be interpreted cautiously and require experimental validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey.
- Department of Pharmacy, Konya Numune Hospital, Republic of Turkey Ministry of Health, Konya 42060, Turkey.
- Department of Midwifery, University of Health Sciences, Istanbul 34668, Turkey.
- Unit of Pharmacovigilance, Dr. Ismail Fehmi Cumalioglu City Hospital, Republic of Turkey Ministry of Health, Tekirdag 59020, Turkey.
ORCID-Profile: Lutfi Cagatay Onar, Ersin Guner, Ibrahim Yilmaz
Zitieren
APA
Onar, L. C., Guner, E., Dalkiran, I. O., & Yilmaz, I. (2026). Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis. Medical Sciences, 14(2), 260. https://doi.org/10.3390/medsci14020260
Vancouver
Onar LC, Guner E, Dalkiran IO, Yilmaz I. Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis. Medical Sciences. 2026;14(2):260. doi:10.3390/medsci14020260
BibTeX
@article{Onar2026,
author = {Onar, Lutfi Cagatay and Guner, Ersin and Dalkiran, Irem Ozten and Yilmaz, Ibrahim},
title = {Thromboinflammatory and Pharmacological Effects of Low-Molecular-Weight Heparins in Acute Venous Thromboembolism: An Integrated Clinical and In Silico Analysis},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {260},
doi = {10.3390/medsci14020260}
}
EUVIMED